Abstract
Emerging infectious diseases, such as COVID-191 and Ebola virus disease,2 pose a major threat to public health. Despite the presence of Ebola virus disease in central and west Africa for several years,2 many African countries are yet to fully utilise genomics in public health. This situation is highlighted by the current COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 By Oct 5, 2020, 9 months into the COVID-19 pandemic, 2980 SARS-CoV-2 genomes sampled from patients with COVID-19, from 21 of 54 African countries, had been deposited in the GISAID database.
Highlights
Emerging infectious diseases, such as COVID-191 and Ebola virus disease,[2] pose a major threat to public health
Despite the presence of Ebola virus disease in central and west Africa for several years,[2] many African countries are yet to fully utilise genomics in public health. This situation is highlighted by the current COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[1]
The absence of genomic data from most African countries shows that the benefits of these data for public health threats are yet to be fully achieved for preparedness and response to emerging infectious diseases
Summary
Emerging infectious diseases, such as COVID-191 and Ebola virus disease,[2] pose a major threat to public health. Using genomics to improve preparedness and response of future epidemics or pandemics in Africa
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
